The Patent Finder
AP

Astellas Pharma Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

146 patents currently held

55 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.

The next term ends in Jan 2027. from the record

Of the 55 now held by other companies, 7 name Tron Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg Universität Mainz Gemeinnützige GmbH as their current owner, and 48 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
39
Ending by 2030
Jan 2027
Next term end
95
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Monoclonal Antibodies Against CLAUDIN-18 for Treatment of Cancer US 8,168,427
The most cited patent in this portfolio, cited by 113 later US patents, top 5% of utility patents granted in 2012 in our data. Protection runs to 2028.
Ends Feb 2028 · High confidence
Also notable
EML4-ALK Fusion Gene US 7,728,120
Cited by 53 later US patents, top 25% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Ends Apr 2028 · High confidence
Also notable
Genetic Products Differentially Expressed in Tumors and the Use Thereof US 9,044,382
Cited by 37 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2027.
Ends Aug 2027 · High confidence

Formerly held, still cited

Notable
Cited by 34 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Ends Aug 2032 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Nov 21 to 28, 2026 · next Nov 21
  • 8 fees due Dec 2 to 23, 2026 · next Dec 2
  • 2 fees due Jan 21 to 25, 2027 · next Jan 21
  • 3 fees due Feb 6 to 22, 2027 · next Feb 6
  • 3 fees due Mar 5 to 24, 2027 · next Mar 5
  • 2 fees due Apr 1 to 24, 2027 · next Apr 1
  • 1 fee due May 28, 2027
    The maintenance fee for Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Metastatic Pancreatic Adenocarcinoma (US 11,826,402) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
  • 3 fees due Jun 15 to 30, 2027 · next Jun 15
  • 1 fee due Jul 14, 2027
    The maintenance fee for Phenyldifluoromethyl-Substituted Prolinamide Compound (US 10,532,979) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.
  • 2 fees due Aug 13 to 23, 2027 · next Aug 13
  • 7 fees due Sep 5 to 30, 2027 · next Sep 5
  • 3 fees due Oct 2 to 14, 2027 · next Oct 2
  • 1 fee due Nov 7, 2027
    The maintenance fee for Antibodies Against Claudin 18.2 Useful in Cancer Diagnosis (US 11,976,130) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 7 of the patents on this record were granted since Aug 21, 2026
  • 4 terms have ended since Aug 21, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 11,739,139Monoclonal Antibodies Against CLAUDIN-18 for Treatment of Cancer
In force
 · High confidence
In forceHigh confidence
US 9,751,934Monoclonal Antibodies Against CLAUDIN-18 for Treatment of Cancer
In force
 · High confidence
In forceHigh confidence
US 7,678,820Hetero Compound
In force
 · High confidence
In forceHigh confidence
US 7,872,097Cyclic Peptide Compounds
In force
 · High confidence
In forceHigh confidence
US 7,638,5362-Acylaminothiazole Derivative or Salt Thereof
In force
 · Medium confidence
In forceMedium confidence
US 9,044,382Genetic Products Differentially Expressed in Tumors and the Use Thereof
In force
 · High confidence
In forceHigh confidence
US 9,932,589EML4-ALK Fusion Gene
In force
 · High confidence
In forceHigh confidence
US 7,879,844Heterocyclic Janus Kinase 3 Inhibitors
In force
 · High confidence
In forceHigh confidence
US 10,206,879Active Ingredient Containing Stabilised Solid Forms and Method for the Production Thereof
In force
 · Medium confidence
In forceMedium confidence
US 10,603,280Active Ingredient Containing Stabilised Solid Medicinal Forms and Methods for the Production Thereof
In force
 · Medium confidence
In forceMedium confidence
10 of 146 patents shown.
Pro members see all 146.
Pro members: see all 146 patents
Also on record, not counted in the 146: 55 patents in force now held by others · 343 patents ended · 74 applications pending · 372 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited